SSGJ-611 (3SBio)

SSGJ-611 is a bispecific monoclonal antibody designed to simultaneously target Programmed Death-Ligand 1 (PD-L1) and Vascular Endothelial Growth Factor (VEGF). Developed by Sunshine Guojian, a subsidiary of 3SBio, the molecule aims to combine the therapeutic benefits of immune checkpoint inhibition and anti-angiogenesis. By blocking PD-L1, SSGJ-611 restores T-cell mediated anti-tumor activity, while its inhibition of VEGF disrupts the tumor's blood supply and normalizes the tumor microenvironment to enhance immune cell infiltration. In late 2024, Pfizer secured the ex-China development and commercialization rights for the candidate in a deal valued at up to $1.25 billion. The drug is currently being evaluated in Phase 3 clinical trials in China for advanced non-small cell lung cancer (NSCLC) and is in Phase 2 development for various other solid tumors.

Other names

PD-L1/VEGFPD-L1/VEGF bispecific antibodySunshine Guojian PD-L1/VEGF